Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings

Small molecule inhibitors of Janus kinase (JAK) family members (JAK1, JAK2, JAK3, and Tyk2) are currently being pursued as potential new modes of therapy for a variety of diseases, including the inhibition of JAK2 for the treatment of myeloproliferative disorders. Selective inhibition within the JAK...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Experimental hematology 2013-05, Vol.41 (5), p.491-500
Hauptverfasser:	Yu, Violeta, Pistillo, Jeanne, Archibeque, Ivonne, Han Lee, Josie, Sun, Bee-Chun, Schenkel, Laurie B, Geuns-Meyer, Stephanie, Liu, Liqin, Emkey, Renee
Format:	Artikel
Sprache:	eng
Schlagworte:	Advanced Basic Science Animals Cell Line Cell Proliferation - drug effects Cells, Cultured Dose-Response Relationship, Drug Hematology, Oncology and Palliative Medicine High-Throughput Screening Assays - methods Humans Janus Kinase 2 - antagonists & inhibitors Janus Kinase 2 - genetics Janus Kinase 2 - metabolism Leukocytes, Mononuclear - drug effects Leukocytes, Mononuclear - metabolism Oncogene Proteins, Fusion - antagonists & inhibitors Oncogene Proteins, Fusion - genetics Oncogene Proteins, Fusion - metabolism Phosphorylation - drug effects Precursor Cells, B-Lymphoid - drug effects Precursor Cells, B-Lymphoid - metabolism Protein Kinase Inhibitors - pharmacology Reproducibility of Results STAT5 Transcription Factor - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!